一年一度的J.P Morgan Healthcare Conference一直是享誉生物医药产业的全球战略风向标和项目对接交易的盛会。旧金山时间2020年1月12日,第38届J.P Morgan Healthcare Conference 会议期间,2020 China Focus 会议上,由誉衡生物独家赞助,Ginger Ding 女士(MyBioGate 投资分析全球总监)主持的路演专场中,数十家创新药物,医疗器械,医疗服务健康,生物医药产业全自动化,AI人工智能辅助新药研发等领域公司带来了精彩的演讲展示。

1579415841988283.jpeg

China Focus 路演专场从第一次推出,就受到了跨境平台合作上最为著名积极的龙头企业鼎力支持。恒瑞医药、FC Capital、 勃林格殷格翰、复星、江苏省产业技术研究院、步长医药的等企业大佬场场出席,可见China Focus 路演的影响力和效力满满。随着国内生物医药企业国际间合作越来越多,各类创新主体都有着独特的自身战略。个体优势,只有结合市场,集思广益,才能做出效益最大化的合作及选择,国际化合作将是未来全球药企发展的必然趋势。

1579415876430280.jpeg

China Focus 路演专场还专门请到了六位重量级嘉宾分享其成功海内外项目对接,融资等成功的经验。嘉宾们针对中美商业文化差异进行了深入交流讨论,大家一致认为:与中国企业打交道的方式越来越国际化、专业化、便利化,对中外商业互通接受度也越来越高,China Focus路演专场正在为更多的国内药企、国际药企、以及海内外投资机构提供更有深度的对接服务,并承担着真正意义上的“引路人”角色。

1579415896779935.jpeg

在随后的China Focus路演专场,依次进行项目展示(公司推广)的是誉衡生物、拜耳(中国)、挚盟医药、开拓药业(Kintor)、惠瑞生物、瑞顺生物、索元生物医药、剂泰医药、Maintect GmbH、Celsion、Targovax(OSE:TRVX)、Flow Pharma、Curevo Vaccine、Cerenetex、Dyadic International、Virometix、OncoGenesis、Strateos、Gero、VivaLNK、Canary Speech、TECLens、Erythra、Avotres等24家中外肿瘤、慢性乙型肝炎、中风、传染病疫苗、医疗物联网平台等业界生物技术和制药的翘楚公司。项目方对企业进行了全方位展示,并和慕名而来的投资人进行现场答疑与深度对接。

Company Presentation Reference:

1. Targovax

Goal: Activate immune system to inhibit cancer

Target: Lung cancer, melanoma

Method: Develop checkpoint inhibitor to activate immune system ➔ produce more T cells

Platform:

◆ Oncolytic virus ➔ To treat T cell targeting specific tumor

◆ Neoantigen vaccine

2.Flowpharma

Goal: To treat virtual disease, cancer

Target: Breast cancer/ Ebola/ cervical cancer

Platform:

◆ FlowVAX, a neoantigen cancer vaccine; high yield but low cost

◆ SEAPAC Delivery platform (cancer vaccines need a good delivery technology)

Strategy:

Virus in the targeted cells (APC) can recognize neopeptide ➔ produce cytokines ➔release and kill cancer cells.

FlowVAX Workflow (4 weeks total)

◆ Sequence cancer cell

◆ AI screen novel neoantigens

◆ In vitro confirmation

Key advantages:

◆ Each APC only recognize one neoantigen

◆ Intensive T cell activation

◆ Safer, cheaper

◆ No immune response

3. Cerenetex

Focuses: delay in stroke care; delayed treatment

Solutions: cerebral hemodynamics that produced by blood flow

Headphone could pick up acoustic signal produced by cerebral hemodynamics ➔ record➔cloud

Application: Reflect whether the stroke treatment is effective

4. Dyadic

Platform: C1 Fungal gene expression platform

C1: myoliophthna thermophila from alkaline soil in Russia

Advantages: High purity of target protein screted, low cost

Application: glycoengineering— C1 is better than yeast, faster, higher yield

5. Maintest

Target: wet age related-macular degeneration (WAMD)

Problem: ¼ patients shows no effect with current treatment

Strategy: anti-angiogenesis treatment via inhibition of VEGF

Stage: They have already developed the antibody AB125, and tested in vitro/ in vivo; confirmed in initial clinical trial.

Workplan:

1.5-2 years: develop kit

3-5 years: clinical trail

6. Zhimeng Biopharma

Target: 1. Anti-virus/ HBV;  2. CNS: epilepsy, pain, stroke

Pipeline:

HBV—Caspid inhibitor; RNA destabilizer; TLR8 agonist

Epilepsy — KCNQ 2/3 opener

Pain — KCNQ 2/3 opener

Stroke — PSD95 antagonist

7. Virometix

Platform:

◆ SVLP: synthetic virus-like particle (30nm)

◆ synthetic antigen mimetic (SAM)

8. Denovo Biopharma

Goal: Using AI driven method to treat schizophrenia, AD

Strategy: transform failed drugs into successful personalized medicine

From the drugs that fail in phase 3 ➔ search new markers  ➔  modify the drug ➔ phase 3

9. Oncogenesis

Goal: To treat cervical cancer

Current situation: HPV DNA screen (not effective)

Strategy:

new protein biomarker –CerMark

iPap self-assembly collector à CerMark POC analyzer

Advantages:

Patients don’t need to return to clinic for Pap test

High specific; high sensitivity

10. Curevo Vaccine

Targeted diseases: shingles; chickenpox

Strategy: CRV101, a synthetic TLR4 agonist, already in phase 1, suitable for children and adults, not a live virus. Look for parterner, look for $20 million for funding

11. Suzhou Kintor Pharma

Target: cancer

Strategy: monotherapy

IPO preparation

12. Huirui Biopharma Company

Target: infectious disease, autoimmune disease, tumor, leukemia

Gap: current anti-flu medicine induces drug resistance

Products: BH103

Decrease lung cytokine levels

Not expect to induce drug resistance

13. Celsion 

Platform: noval nanoparticle-based technology

◆ LTSL (lipidsome for delivery)— ThermoDOX

◆ Theroplas—GEN-1 immunotherapy

Using DNA plasmid coded for therapeutic protein as a drug

Milestone events:

Targeting hepatocellular carcinoma

ThermaDOX+ radio frequency ablation (RFA)  ➔ expand the treatment zone ➔ survival time increase 2 years

14. WYZE Biotech

Target: acute myeloid leukemia (AML)

Platform: DNT cells (CD3+ CD4- CD8- cells)= double negative T cells ( DNT)

DNT cells are a novel therapy to target AML, effective in eliminating AML

15. Strateos

Goal: accelerating discovery

Platform: using AI, open access, fully-automated, programmable lab

Strategy: Automated chemical synthesis ➔ auto biotestingà product ➔ automated chemical synthesis

16. Gloria Bioscience

Products: GLS-010 fully anti-human PL-1 (naturally screened from transgenic rat platform)

Preliminary Results: Shows impressive antitumor activity when treated on cervical cancer

17. Avotres

Pipeline: 3 year development plan, exit by 2022

Strategy: Find a way to treat regulatory T cells (which can secrete cytokines)

Product: AVT002

18. Gero

Goal: drug discovery against complex diseases

Solution: “Deep phenotype”—model of disease progression with actionable biomarker from large unbiased human cohorts.

Machine learning

Ongoing: Using immune senescence, metabolic health, senescent cells burden as targets to develop anti-aging drugs.

19. Bayer

Right timing and Right places to develop the company in China.

Focus on: cardiovascular and cerebrovascular diseases; diabetes; respiratory disease; cancer; infectious disease

20. Viva LNK

Product: one small device can continuously measure blood pressure, respiration, ECG/HR, temperature, heart failure detection.

21. Canary Speech

Speech can reflect the central nervous system.

Strategy: identify more than 2000 biomarkers in language, to detect neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s’ disease.

22. Teclens

Products: Teclens, contains vitamin B2 + 375nm low intensity UV light in surgery.

Advantages: The lens move along with the eyeballs, no laser risk.

23. METiS Pharmaceutic

Strategy: AI design Nano carrier for drug ➔ Bioassay testing

Machine learning: from expert experience, trail-end-error

24. Erythra

Focus on diagnosis

Product: marker_KIT

Bad blood sample collections ➔ prepare homogenize ➔ create marker KIT